Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of H ...

A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...

Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons,” published in the November 2024 issue of Infectious ...

Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.

Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to ...

A new HIV prevention drug, lenacapavir, has shown 100% effectiveness in women and near-perfect results in men during trials.

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...

"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...

A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...

Discover the groundbreaking results of Lenacapavir, a twice-yearly injection that reduces HIV infection risk offering an ...